Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.

摘要: Summary This study investigated the clinical activity and toxicity of R-HCVAD-AM [rituximab plus HyperCVAD (R-HCVAD) alternating with high-dose cytarabine methotrexate (AM)] in patients newly diagnosed Mantle Cell Lymphoma (MCL). Patients aged ≤70 years confirmed MCL received four cycles each R-HCVAD AM. who obtained a partial response proceeded to autologous stem cell transplant. Sixty-three were enrolled 60 fully eligible. Median age was 57 years (22–66); 60%, 33% 7% classified at low (L)-, intermediate (I)- or high (H)-risk, respectively, according International Prognostic Index (MIPI). Only 22 (37%) completed three died during therapy. Overall complete rates 83% 72% respectively. After median follow-up 46 months (range 1–72) estimated 5-year overall survival (OS) progression-free 73% [95% confidence interval (CI) 59–83%], 61% (95%CI 45–73%) MIPI maintained prognostic value an OS 89%, 80% 24% for L, I, H groups respectively (P < 0·001). This multicentre confirms that is active regimen initial treatment MCL, but associated significant toxicity.